NBRV - ナブリバ・セラピュ―ティクス (Nabriva Therapeutics plc)

NBRVのニュース

   Nabriva Therapeutics Earnings, Revenue Beat in Q3  2020/11/06 00:00:00 Investing.com
Nabriva Therapeutics Earnings, Revenue Beat in Q3
   The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping  2020/11/05 12:54:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) Immunovant Inc (NASDAQ: IMVT ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Laboratory Corp.
   The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings  2020/11/04 13:21:27 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 3) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) BioLineRx ADR Representing 15 Ord Shs (NASDAQ: BLRX )(reacted to positive readout for its stem cell therapy to treat cancer) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(reacted to its quarterly results) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) ( reported strong results for the third quarter) Immunovant Inc (NASDAQ: IMVT ) Scholar Rock Holding Corp (NASDAQ: SRRK ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 3) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aprea Therapeutics Inc (NASDAQ: APRE ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Benitec Biopharma Inc (NASDAQ: BNTC ) Esperion Therapeutics Inc (NASDAQ: ESPR ) (reacted to its quarterly results) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Jaguar Health Inc (NASDAQ: JAGX ) Liminal BioSciences Inc (NASDAQ: LMNL ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Opthea Spon (NASDAQ: OPT ) Silence Therapeutics ADR (NASDAQ: SLN ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Bristol-Myers Squibb Says Antitrust Waiting Period For Proposed Myokardia Acquisition Expires Bristol-Myers Squibb Co (NYSE: BMY ) said the waiting period under the HSR Act in connection with its previously announced tender offer to acquire …
   The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure  2020/11/03 12:38:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) FSD Pharma Inc (NASDAQ: HUGE ) Galecto Inc (NASDAQ: GLTO ) (went public Thursday) Hoth Therapeutics Inc (NASDAQ: HOTH ) Inhibrx Inc (NASDAQ: INBX ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Monopar Therapeutics Inc (NASDAQ: MNPR ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) (halted dosing in Strimvelis study after it was linked to the development of leukemia in a patient) Orphazyme A S ADR (NASDAQ: ORPH ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) Stocks In Focus Aurinia Ends Dry Eye Disease Study Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of …
   Nabriva Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020  2020/11/02 21:01:00 GlobeNewswire
DUBLIN, Ireland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization…
   42 Stocks Moving in Thursday's Pre-Market Session  2020/07/16 11:22:08 Benzinga Feeds
Gainers Nabriva Therapeutics plc (NASDAQ: NBRV ) shares rose 48.9% to … Full story available on Benzinga.com
   Nabriva inks Sivextro distribution with Merck (NASDAQ:NBRV)  2020/07/15 20:11:34 Seeking Alpha
Nabriva Therapeutics (NASDAQ:NBRV) enters into an agreement with subsidiaries of Merck (NYSE:MRK) granting them exclusive distribution rights to antibiotic
   WEP Clinical entre en partenariat avec Nabriva Therapeutics pour la délivrance de XENLETA® (léfamuline) à des patients désignés  2020/07/06 21:18:00 Business Wire
LONDRES--(BUSINESS WIRE)--WEP Clinical (WEP), une société de services pharmaceutiques spécialisés, vient de signer un accord exclusif avec Nabriva Therapeutics (Nabriva) pour la délivrance de XENLETA® (léfamuline) dans le cadre d'un programme de patients désignés ou d'accès élargi. Le programme de patients désignés (NPP) est conçu pour garantir que les médecins, sous réserve de répondre aux critères d'éligibilité et d'obtenir une approbation, peuvent obtenir la formulation intraveineuse ou par
   WEP Clinical kooperiert mit Nabriva Therapeutics bei der Versorgung einzelner Patienten mit XENLETA® (Lefamulin)  2020/07/06 18:17:00 Business Wire
LONDON--(BUSINESS WIRE)--WEP Clinical (WEP), ein Unternehmen mit Schwerpunkt auf pharmazeutischen Dienstleistungen, hat mit Nabriva Therapeutics (Nabriva) einen Exklusivvertrag über die Bereitstellung von XENLETA® (Lefamulin) für einzelne Patienten bzw. auf Basis eines erweiterten Zugangs unterzeichnet. Sofern sie die erforderlichen Anforderungen erfüllen und die Berechtigung erhalten, sollen Ärzte im Rahmen des Named Patient Program (NPP) XENLETA® zur oralen oder intravenösen Behandlung anford
   WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA® (lefamulin)  2020/07/06 11:00:00 Business Wire
LONDON--(BUSINESS WIRE)--WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet availab
   42 Stocks Moving in Thursday's Pre-Market Session  2020/07/16 11:22:08 Benzinga Feeds
Gainers Nabriva Therapeutics plc (NASDAQ: NBRV ) shares rose 48.9% to … Full story available on Benzinga.com
   Nabriva inks Sivextro distribution with Merck (NASDAQ:NBRV)  2020/07/15 20:11:34 Seeking Alpha
Nabriva Therapeutics (NASDAQ:NBRV) enters into an agreement with subsidiaries of Merck (NYSE:MRK) granting them exclusive distribution rights to antibiotic
   WEP Clinical entre en partenariat avec Nabriva Therapeutics pour la délivrance de XENLETA® (léfamuline) à des patients désignés  2020/07/06 21:18:00 Business Wire
LONDRES--(BUSINESS WIRE)--WEP Clinical (WEP), une société de services pharmaceutiques spécialisés, vient de signer un accord exclusif avec Nabriva Therapeutics (Nabriva) pour la délivrance de XENLETA® (léfamuline) dans le cadre d'un programme de patients désignés ou d'accès élargi. Le programme de patients désignés (NPP) est conçu pour garantir que les médecins, sous réserve de répondre aux critères d'éligibilité et d'obtenir une approbation, peuvent obtenir la formulation intraveineuse ou par
   WEP Clinical kooperiert mit Nabriva Therapeutics bei der Versorgung einzelner Patienten mit XENLETA® (Lefamulin)  2020/07/06 18:17:00 Business Wire
LONDON--(BUSINESS WIRE)--WEP Clinical (WEP), ein Unternehmen mit Schwerpunkt auf pharmazeutischen Dienstleistungen, hat mit Nabriva Therapeutics (Nabriva) einen Exklusivvertrag über die Bereitstellung von XENLETA® (Lefamulin) für einzelne Patienten bzw. auf Basis eines erweiterten Zugangs unterzeichnet. Sofern sie die erforderlichen Anforderungen erfüllen und die Berechtigung erhalten, sollen Ärzte im Rahmen des Named Patient Program (NPP) XENLETA® zur oralen oder intravenösen Behandlung anford
   WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA® (lefamulin)  2020/07/06 11:00:00 Business Wire
LONDON--(BUSINESS WIRE)--WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet availab

calendar